Catalyst Biosciences, Inc. Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics; Catalyst Will Receive Milestone up to $195 Million
7/7/2009 7:20:08 AM
More...
|
Wyeth (WYE), Catalyst Biosciences, Inc. Sign Deal Worth Potentially $500 Million
6/30/2009 7:03:35 AM
More...
|
Catalyst Biosciences, Inc. Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development
3/24/2009 12:12:44 PM
More...
|
Catalyst Biosciences, Inc. Raises $40 Million in Series C Financing
12/3/2008 6:42:53 AM
More...
|
Catalyst Biosciences, Inc. Appoints Dr. Todd Lorenz Chief Medical Officer
10/28/2008 8:14:08 AM
More...
|
Catalyst Biosciences, Inc. Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
5/7/2008 7:24:59 AM
More...
|
Catalyst Biosciences, Inc. and Centocor Research And Development, Inc. Form Collaboration to Discover and Develop Engineered Protease Therapeutics
1/7/2008 6:54:05 AM
More...
|
Catalyst Biosciences, Inc. Appoints Erik Wiberg Chief Financial Officer
2/1/2007 10:09:13 AM
More...
|
The Day In Review: Seattle Genetics, Inc. (SGEN) Sells Cancer Drug To Genentech, Inc. (DNA)
1/8/2007 6:38:07 PM
More...
|
Catalyst Biosciences, Inc. And Wyeth Pharmaceuticals Sign Two Agreements For Novel Biotherapeutic Platform Of Engineered Proteases
1/8/2007 12:31:24 PM
More...
|
|